Reviewer’s report

Title: Cost of Antipsychotic Polypharmacy in the Treatment of Schizophrenia

Version: 1 Date: 31 December 2007

Reviewer: Hans Rittmannsberger

Reviewer’s report:

The discussion is more balanced now and I think that the paper will be apt for publication.

Minor essential revisions:

As stated in my first review I consider direct comparisons between the 3 investigated drugs as inappropriate. So I disagree with the term "medication costs savings" (page 14, 2nd paragraph) since that implies, that all drugs were given for the same purposes, which cannot be proven and is not the case to my opinion.

Discretionary revisions:

The authors could provide a clearer picture of the prescribing patterns if they investigated to what extent an antipsychotic medication was present when the new drug was initiated. This would allow to distinguish between "switch" cases and "add-on" cases.

Tables were not available.

What next?: Accept after minor essential revisions

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

I declare that I have no competing interests.